gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · KPRXHealthcarePharmaceuticals

Kiora Pharmaceuticals, Inc. Common Stock (KPRX)

$1.66−4.05%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$1.73▼ 29.96% in range
Nov 3, 2025Low $1.56 · High $2.86Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Kiora Pharmaceuticals closed at $1.66 on Nov 4, down 4.05%, 42.0% below its 52-week closing high. Volume of 11.2K shares was 0.19× its 20-day average (below normal).

Split-adjusted performance: -33.6% over one month, -33.9% over six months, -32.8% over one year.

Short interest was 4.2K shares at the Oct 15 settlement, up 22.3% from the prior report (0.1% of float, 1.0 days to cover).

Market cap$7.3M4.4M shares
Revenue · quarter$0.00—
Diluted EPS$-0.34—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range1.56 – 2.86−42.0% from high
Volume11.2K0.19× 20-day avg
Volatility · 60d73.7%Annualised
Short % of float0.1%1.0 days to cover
Net cash$16.8MCash $16.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −29.7%1M −33.6%3M −35.2%6M −33.9%YTD −15.7%1Y −32.8%3Y −69.3%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum39
Revenue growth—
Net margin—
Value (low P/E)—
Size12

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short4.2K+22.3% vs prior
Days to cover1.0Settled Oct 15
% of float0.1%
Short vol. 10d40.5%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
KPRXKiora Pharmaceuticals$1.66−4.05%−33.9%———$7.3M
ALZNAlzamend Neuro$1.53+4.79%+39.1%———$7.4MCompare
ENSCEnsysce Biosciences$0.3697−2.12%−5.2%−15.1%−220.8%—$7.2MCompare
SNGXSoligenix$0.3508−1.49%+6.0%———$7.6MCompare
NAIINatural Alternatives International$1.10+3.77%−59.6%+1.9%−39.2%—$6.9MCompare
FBLGFibroBiologics$0.9685−2.17%−24.9%———$6.9MCompare
VTGNVistagen Therapeutics$0.1843+9.70%−69.8%+504.9%−882.8%—$8.2MCompare
ENVBEnveric Biosciences$1.46−2.67%−54.1%———$6.5MCompare
XCURExicure$0.9928−1.70%−70.7%———$6.5MCompare

News about Kiora Pharmaceuticals

All news →

No recent articles focused on Kiora Pharmaceuticals.

Quick answers

What does Kiora Pharmaceuticals do?
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
What is KPRX's market cap?
$7.34M, based on the Nov 4 close of $1.66.
Does Kiora Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of KPRX is sold short?
4.2K shares, 0.1% of float, as of Oct 15, 2026.
What sector is KPRX in?
Healthcare, in the Pharmaceuticals industry.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

HQ: Encinitas, CA13 employeesListed Feb 13, 2015kiorapharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology